Anti-Mouse CD152 (CTLA-4) APC

Grouped product items
SizePrice Qty
25 μg
100 μg

Additional UC10-4F10-11 Formats

Cat.No.FormatStarting From
14612-60PE$ 60.00
14612-80APC$ 85.00
14612-25SAFIRE Purified$ 145.00
14612-77PE-Cyanine7$ 115.00
14612-20Purified$ 120.00
Catalog Number : 14612-80


The UC10-4F10-11 monoclonal antibody specifically reacts with the mouse Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4), also known as CD152. It is a protein with a structure similar to CD28 regarding the genomic organization, amino acid sequence, and structure. CTLA-4 is expressed on activated T cells and CD25+/CD4+ Treg lymphocytes and binds the members of the B7 family, B7-1 (CD80) and B7-2 (CD86), with higher affinity than CD28. CD28 seems to provide opposing signal to T lymphocytes, while CD152 inhibits the T lymphocytes progression to an activated state and their proliferation, CD28 is a costimulator.

The mouse UC10 -4F10-11 monoclonal antibody does not cross-react with the rat leukocytes.

Additional Information

Armenian Hamster IgG
Research Interest:Adaptive Immunity
Cell Type:T Cells, T Regulatory Cells
The product should be stored undiluted at 4°C and should be protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.
Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, ph7.2.

Alegre, M. L., Noel, P. J., Eisfelder, B. J., Chuang, E., Clark, M. R., Reiner, S. L., & Thompson, C. B. (1996). Regulation of surface and intracellular expression of CTLA4 on mouse T cells. The Journal of Immunology157(11), 4762-4770.

Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., ... & Bluestone, J. A. (1994). CTLA-4 can function as a negative regulator of T cell activation. Immunity1(5), 405-413.

Cilio, C. M., Daws, M. R., Malashicheva, A., Sentman, C. L., & Holmberg, D. (1998). Cytotoxic T Lymphocyte Antigen 4 Is Induced in the Thymus upon In Vivo Activation and Its Blockade Prevents Anti-CD3–mediated Depletion of Thymocytes. The Journal of experimental medicine188(7), 1239-1246.

© BioGems International, Inc. All rights reserved.